Ironwood Pharmaceuticals Inc (IRWD) stock
Close on Nov 17, 2026Market cap $804.72MP/E 6.3Yield –
Ironwood Pharmaceuticals Inc grew revenue 26.2% to $389.32M over the twelve months to Jun 30, 2026. Operating income rose 219.3% to $234.17M, moving the operating margin from 23.8% to 60.1%. Free cash flow was $127.01M, up 22.8% from a year earlier. At the latest close the market valued the company at $804.72M, 6.3 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $804.72M
- P/E ratio
- 6.3
- Price to sales
- 2.07
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $389.32M
- Net income
- $129.87M
- EPS, diluted
- $0.77
- Free cash flow
- $127.01M
- Book value per share
- -$0.97
- Diluted shares
- 167M
Trading
- Next earnings
- Feb 24, 2027 (estimated, before the open)
- Previous close
- $4.85
- Open
- $4.83
- Day's range
- $4.76 – $4.89
- Volume
- 2,824,897
- Average volume (20 days)
- 2,534,393
- Index membership
- Russell 2000, Russell 3000
- 52-week range
- $2.95 – $5.78
- RSI (14 days)
- 75.3
- Volatility (1 year)
- 78.6%
- Relative volume
- 1.49×
On 1 of our idea list: Turnarounds
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | IRWD | S&P 500 | Difference | IRWD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +39.1% | -4.0% | +43.2 pts | ||
| 3 months | +11.7% | -5.0% | +16.7 pts | ||
| Year to date | +44.5% | +8.2% | +36.3 pts | ||
| 1 year | +55.6% | +11.2% | +44.4 pts | ||
| 3 years | -50.2% | +68.5% | −118.7 pts | -20.7% | +19.0% |
| 5 years | -60.0% | +67.3% | −127.3 pts | -16.7% | +10.8% |
| 10 years | -64.1% | +291.6% | −355.7 pts | -9.7% | +14.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ironwood Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Ironwood Pharmaceuticals
Pharmaceutical Preparations
Ironwood Pharmaceuticals, Inc. is a biotechnology company that researches, develops, and commercializes therapies for individuals affected by gastrointestinal and rare diseases. Its primary commercial medicine is linaclotide, branded as LINZESS and CONSTELLA, which is a guanylate cyclase type C agonist. The business also advances clinical-stage drug candidates, notably apraglutide for short bowel syndrome. Its treatments serve adult and pediatric patients with conditions such as irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation.
Company profile, executives and historyIronwood Pharmaceuticals stock: common questions
What is Ironwood Pharmaceuticals's stock price?
IRWD closed at $4.87 on Nov 17, 2026, up 0.41% on the day. Over the past 52 weeks it traded between $2.95 and $5.78.
What is Ironwood Pharmaceuticals's market cap?
Ironwood Pharmaceuticals was worth $804.72M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is IRWD's P/E ratio?
IRWD trades at 6.3 times earnings, based on diluted earnings per share of $0.77 over the twelve months to Jun 30, 2026.
How much revenue does Ironwood Pharmaceuticals make?
Ironwood Pharmaceuticals reported revenue of $389.32M for the twelve months to Jun 30, 2026, up 26.2% from a year earlier.
Does Ironwood Pharmaceuticals pay a dividend?
No. Ironwood Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Ironwood Pharmaceuticals report earnings next?
Ironwood Pharmaceuticals is expected to report Q4 FY2026 results on Feb 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IRWD stock performed over the past year?
Including dividends, IRWD returned +55.6% over the past year, against +11.2% for the S&P 500.
How many IRWD shares are sold short?
15M shares were sold short at the latest FINRA report, 10.71% of the float, or 9.8 days of average trading volume.
Who are Ironwood Pharmaceuticals's competitors?
Companies most similar to Ironwood Pharmaceuticals by business, industry and size include ARDX, MIRM, MNKD, RARE, XERS.
See a number that looks wrong?